Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Insulin glargine
INDICATION: Diabetes mellitus type 2
DATE: 25/02/2019
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
